• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tevogen Bio Holdings Inc. - Common Stock (NQ: TVGN )

    0.2790 -0.0210 (-7.00%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 483,073
    Open 0.3000
    Bid (Size) 0.2900 (99)
    Ask (Size) 0.3100 (38)
    Prev. Close 0.3000
    Today's Range 0.2717 - 0.3100
    52wk Range 0.2717 - 21.09
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
    From Tevogen Bio Inc
    Via GlobeNewswire
    Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Via Benzinga

    Performance

    YTD
    -97.21%
    -97.21%
    1 Month
    -41.30%
    -41.30%
    3 Month
    -60.14%
    -60.14%
    6 Month
    -90.45%
    -90.45%
    1 Year
    -97.21%
    -97.21%

    More News

    Read More
    Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
    From Tevogen Bio Inc
    Via GlobeNewswire
    CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
    From Tevogen Bio Inc
    Via GlobeNewswire
    Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Set to Join Russell 3000® Index
    From Tevogen Bio Inc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
    From Tevogen Bio Inc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
    From Tevogen Bio Inc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
    From Tevogen Bio Inc
    Via GlobeNewswire
    TVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024
    Via InvestorPlace
    Tevogen Bio Reports First Quarter 2024 Financial Results
    From Tevogen Bio Inc
    Via GlobeNewswire
    Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.